Predictors of disease activity in 857 patients with MS treated with interferon beta-1b

Hans Peter Hartung, Ludwig Kappos, Douglas S. Goodin, Paul O’Connor, Massimo Filippi, Barry Arnason, Giancarlo Comi, Stuart Cook, Douglas Jeffery, John Petkau, Richard White, Timon Bogumil, Karola Beckmann, Brigitte Stemper, Gustavo Suarez, Rupert Sandbrink, Christoph Pohl

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Multiple sclerosis (MS) is a chronic demyelinating neurodegenerative disease of the CNS that requires long-term treatment. The identification of patient characteristics that can help predict disease outcomes could improve care for patients with MS. The objective of this study is to identify predictors of disease activity in patients from the BEYOND trial. This regression analysis of patients with relapsing–remitting MS from BEYOND examined the predictive value of patient characteristics at baseline and after 1 year of treatment with interferon beta-1b 250 μg every other day for clinical and MRI outcomes after year 1 of the study. 857 and 765 patients were included in the analyses of clinical and MRI outcomes, respectively. In multivariate analyses of age, a higher number of relapses in the past 2 years, ≥3 new MRI lesions in the first year, and, especially, a higher number of relapses in year 1 predicted the future occurrence of relapses. By contrast, age, MRI activity, and the presence of neutralizing antibodies in the first year were principally predictive of future MRI activity. In patients with continued clinical disease activity or substantial MRI activity on therapy, an alternative therapeutic approach should be strongly considered.

Original languageEnglish
JournalJournal of Neurology
DOIs
Publication statusAccepted/In press - Aug 5 2015

Fingerprint

Multiple Sclerosis
Recurrence
Demyelinating Diseases
Complementary Therapies
Neutralizing Antibodies
Neurodegenerative Diseases
Interferon beta-1b
Patient Care
Therapeutics
Multivariate Analysis
Regression Analysis

Keywords

  • Interferon beta-1b
  • MRI lesion
  • Multiple sclerosis
  • Predictor
  • Relapse

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Hartung, H. P., Kappos, L., Goodin, D. S., O’Connor, P., Filippi, M., Arnason, B., ... Pohl, C. (Accepted/In press). Predictors of disease activity in 857 patients with MS treated with interferon beta-1b. Journal of Neurology. https://doi.org/10.1007/s00415-015-7862-9

Predictors of disease activity in 857 patients with MS treated with interferon beta-1b. / Hartung, Hans Peter; Kappos, Ludwig; Goodin, Douglas S.; O’Connor, Paul; Filippi, Massimo; Arnason, Barry; Comi, Giancarlo; Cook, Stuart; Jeffery, Douglas; Petkau, John; White, Richard; Bogumil, Timon; Beckmann, Karola; Stemper, Brigitte; Suarez, Gustavo; Sandbrink, Rupert; Pohl, Christoph.

In: Journal of Neurology, 05.08.2015.

Research output: Contribution to journalArticle

Hartung, HP, Kappos, L, Goodin, DS, O’Connor, P, Filippi, M, Arnason, B, Comi, G, Cook, S, Jeffery, D, Petkau, J, White, R, Bogumil, T, Beckmann, K, Stemper, B, Suarez, G, Sandbrink, R & Pohl, C 2015, 'Predictors of disease activity in 857 patients with MS treated with interferon beta-1b', Journal of Neurology. https://doi.org/10.1007/s00415-015-7862-9
Hartung, Hans Peter ; Kappos, Ludwig ; Goodin, Douglas S. ; O’Connor, Paul ; Filippi, Massimo ; Arnason, Barry ; Comi, Giancarlo ; Cook, Stuart ; Jeffery, Douglas ; Petkau, John ; White, Richard ; Bogumil, Timon ; Beckmann, Karola ; Stemper, Brigitte ; Suarez, Gustavo ; Sandbrink, Rupert ; Pohl, Christoph. / Predictors of disease activity in 857 patients with MS treated with interferon beta-1b. In: Journal of Neurology. 2015.
@article{03a94cfde0e54162a83a24786e557e16,
title = "Predictors of disease activity in 857 patients with MS treated with interferon beta-1b",
abstract = "Multiple sclerosis (MS) is a chronic demyelinating neurodegenerative disease of the CNS that requires long-term treatment. The identification of patient characteristics that can help predict disease outcomes could improve care for patients with MS. The objective of this study is to identify predictors of disease activity in patients from the BEYOND trial. This regression analysis of patients with relapsing–remitting MS from BEYOND examined the predictive value of patient characteristics at baseline and after 1 year of treatment with interferon beta-1b 250 μg every other day for clinical and MRI outcomes after year 1 of the study. 857 and 765 patients were included in the analyses of clinical and MRI outcomes, respectively. In multivariate analyses of age, a higher number of relapses in the past 2 years, ≥3 new MRI lesions in the first year, and, especially, a higher number of relapses in year 1 predicted the future occurrence of relapses. By contrast, age, MRI activity, and the presence of neutralizing antibodies in the first year were principally predictive of future MRI activity. In patients with continued clinical disease activity or substantial MRI activity on therapy, an alternative therapeutic approach should be strongly considered.",
keywords = "Interferon beta-1b, MRI lesion, Multiple sclerosis, Predictor, Relapse",
author = "Hartung, {Hans Peter} and Ludwig Kappos and Goodin, {Douglas S.} and Paul O’Connor and Massimo Filippi and Barry Arnason and Giancarlo Comi and Stuart Cook and Douglas Jeffery and John Petkau and Richard White and Timon Bogumil and Karola Beckmann and Brigitte Stemper and Gustavo Suarez and Rupert Sandbrink and Christoph Pohl",
year = "2015",
month = "8",
day = "5",
doi = "10.1007/s00415-015-7862-9",
language = "English",
journal = "Journal of Neurology",
issn = "0340-5354",
publisher = "Dr. Dietrich Steinkopff Verlag GmbH and Co. KG",

}

TY - JOUR

T1 - Predictors of disease activity in 857 patients with MS treated with interferon beta-1b

AU - Hartung, Hans Peter

AU - Kappos, Ludwig

AU - Goodin, Douglas S.

AU - O’Connor, Paul

AU - Filippi, Massimo

AU - Arnason, Barry

AU - Comi, Giancarlo

AU - Cook, Stuart

AU - Jeffery, Douglas

AU - Petkau, John

AU - White, Richard

AU - Bogumil, Timon

AU - Beckmann, Karola

AU - Stemper, Brigitte

AU - Suarez, Gustavo

AU - Sandbrink, Rupert

AU - Pohl, Christoph

PY - 2015/8/5

Y1 - 2015/8/5

N2 - Multiple sclerosis (MS) is a chronic demyelinating neurodegenerative disease of the CNS that requires long-term treatment. The identification of patient characteristics that can help predict disease outcomes could improve care for patients with MS. The objective of this study is to identify predictors of disease activity in patients from the BEYOND trial. This regression analysis of patients with relapsing–remitting MS from BEYOND examined the predictive value of patient characteristics at baseline and after 1 year of treatment with interferon beta-1b 250 μg every other day for clinical and MRI outcomes after year 1 of the study. 857 and 765 patients were included in the analyses of clinical and MRI outcomes, respectively. In multivariate analyses of age, a higher number of relapses in the past 2 years, ≥3 new MRI lesions in the first year, and, especially, a higher number of relapses in year 1 predicted the future occurrence of relapses. By contrast, age, MRI activity, and the presence of neutralizing antibodies in the first year were principally predictive of future MRI activity. In patients with continued clinical disease activity or substantial MRI activity on therapy, an alternative therapeutic approach should be strongly considered.

AB - Multiple sclerosis (MS) is a chronic demyelinating neurodegenerative disease of the CNS that requires long-term treatment. The identification of patient characteristics that can help predict disease outcomes could improve care for patients with MS. The objective of this study is to identify predictors of disease activity in patients from the BEYOND trial. This regression analysis of patients with relapsing–remitting MS from BEYOND examined the predictive value of patient characteristics at baseline and after 1 year of treatment with interferon beta-1b 250 μg every other day for clinical and MRI outcomes after year 1 of the study. 857 and 765 patients were included in the analyses of clinical and MRI outcomes, respectively. In multivariate analyses of age, a higher number of relapses in the past 2 years, ≥3 new MRI lesions in the first year, and, especially, a higher number of relapses in year 1 predicted the future occurrence of relapses. By contrast, age, MRI activity, and the presence of neutralizing antibodies in the first year were principally predictive of future MRI activity. In patients with continued clinical disease activity or substantial MRI activity on therapy, an alternative therapeutic approach should be strongly considered.

KW - Interferon beta-1b

KW - MRI lesion

KW - Multiple sclerosis

KW - Predictor

KW - Relapse

UR - http://www.scopus.com/inward/record.url?scp=84938634498&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938634498&partnerID=8YFLogxK

U2 - 10.1007/s00415-015-7862-9

DO - 10.1007/s00415-015-7862-9

M3 - Article

JO - Journal of Neurology

JF - Journal of Neurology

SN - 0340-5354

ER -